Big day for biotech

Shares of Puma Biotechnology gained roughly 300 percent, on positive results of an experimental breast cancer drug in a late stage trial. Biogen Idec saw its shares climb on surging sales of its new multiple sclerosis drug. What’s behind the numbers at Puma and Biogen Idec and what can investors look forward to?

This entry was posted in Biotech & Pharmaceuticals, NBR Show Clips. Bookmark the permalink.

Leave a Reply